NR4A1 and breast cancer: In another clinical trial comparing outcomes in patients with metastatic hormone receptor positive BC who received eribulin (antitubulin antimitotic agent) with or without pembrolizumab (anti-PD-1 agent), a shift in the abundance of Akkermansia and Faecalibacterium after two cycles of therapy was described.